⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XNCR News
Xencor, Inc.
Xencor to Participate at Upcoming Investor Conferences
businesswire.com
XNCR
Primmune Therapeutics Appoints Chief Medical Officer and Executive Board Chair; Establishes Melanoma Clinical Study Advisory Board
globenewswire.com
ALGN
AZN
EXEL
VRTX
XNCR
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
businesswire.com
XNCR
Incyte Japan annonce l’autorisation de Minjuvi ® (tafasitamab) en association avec le rituximab et le lénalidomide pour le traitement du lymphome folliculaire récidivant ou réfractaire
businesswire.com
INCY
XNCR
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
businesswire.com
INCY
XNCR
Montara Therapeutics Announces Development Candidate for First BrainOnly™-Enabled Program in TSC-Related Epilepsy and Appoints Chief Business Officer
globenewswire.com
XNCR
AMGN
Xencor to Participate at Upcoming Investor Conferences
businesswire.com
XNCR
Xencor Reports Third Quarter 2025 Financial Results
businesswire.com
XNCR
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
businesswire.com
XNCR
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
prnewswire.com
GTBP
EVAX
RNXT
EDAP
XNCR
GTBP
EVAX
RNXT
EDAP
XNCR